Status:
COMPLETED
Pharmacokinetic Properties of Sertraline Before and After Gastric Bypass Surgery
Lead Sponsor:
North Dakota State University
Collaborating Sponsors:
National Institutes of Health (NIH)
Conditions:
Roux en Y Gastric Bypass Surgery
Eligibility:
All Genders
18-60 years
Phase:
PHASE3
Brief Summary
This study is being conducted to evaluate how the body absorbs and processes the medication sertraline (Zoloft®) before compared to how it is absorbed at two time points after gastric bypass surgery. ...
Eligibility Criteria
Inclusion
- 1\. Male or female between 18 and 60 years of age at the time of Informed Consent
- 2\. Scheduled to undergo Roux en Y Gastric Bypass Surgery (RYGBP) or in evaluation for surgery prior to scheduling at the investigators' discretion.
- 3\. Ability to swallow whole medication tablets and eat solid foods
Exclusion
- 1\. Those taking any medication at the time of the study which has a known, clinically significant, drug-interaction with sertraline, which may affect participant safety or threaten the validity of the data.
- 2\. Hypersensitivity to sertraline or any excipient contained in either the tablet or solution
- 3\. Inability to tolerate blood draws
- 4\. History of or current bipolar disorder, psychotic disorder, or current major depressive disorder or suicidality, or other psychiatric condition that the investigator feels may put the subject at additional risk by participating in the study
- 5\. Alcohol or other substance abuse in the past four weeks or dependence in the past year
- 6\. Currently pregnant or lactating or any participant who wants to become pregnant during the study
- 7\. Female participant unwilling to use an accepted method of birth control during the study assessment periods.
- 8\. Disulfiram or metronidazole at baseline (due to small percentage of alcohol in sertraline solution) or other medication with a similar interaction with a very small amount of alcohol
- 9\. Inability or unwillingness to avoid alcohol or grapefruit juice for the required study duration
- 10\. Baseline medications which significantly alter gastrointestinal transit time (e.g. oral anticholinergic medications, metoclopramide, erythromycin) and are taken on a routinely scheduled basis. In addition, any such medication cannot be taken in close proximity (minimum of five half-lives of the drug) to the study sertraline administration.
- 11\. Medical condition which may increase participant risk with sertraline
- 12\. Hepatic insufficiency (Hepatic insufficiency will be defined as any liver enzyme test on a standard hepatic panel of greater than or equal to twice the upper limit of normal, or any other hepatic abnormality identified on physical exam, self-report, or laboratory testing that puts the participant at risk in the opinion of the study physician or physician assistant.)
- 13\. History of daily tobacco product use in the past six months
- 14\. Participants who have undergone any type of prior surgical procedure for weight loss
- 15\. Significant Latex allergy (liquid form has a latex dropper)
- 16\. Participant employed by, or who has immediate family employed by NRI
- 17\. History of Hepatitis or HIV Infection
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2014
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT01214382
Start Date
October 1 2010
End Date
August 1 2014
Last Update
April 6 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neuropsychiatric Research Institute
Fargo, North Dakota, United States, 58103